BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 18701909)

  • 1. Enhancing transduction of the liver by adeno-associated viral vectors.
    Nathwani AC; Cochrane M; McIntosh J; Ng CY; Zhou J; Gray JT; Davidoff AM
    Gene Ther; 2009 Jan; 16(1):60-9. PubMed ID: 18701909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application.
    Monahan PE; Lothrop CD; Sun J; Hirsch ML; Kafri T; Kantor B; Sarkar R; Tillson DM; Elia JR; Samulski RJ
    Mol Ther; 2010 Nov; 18(11):1907-16. PubMed ID: 20700109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.
    Finn JD; Hui D; Downey HD; Dunn D; Pien GC; Mingozzi F; Zhou S; High KA
    Mol Ther; 2010 Jan; 18(1):135-42. PubMed ID: 19904235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.
    Nathwani AC; Rosales C; McIntosh J; Rastegarlari G; Nathwani D; Raj D; Nawathe S; Waddington SN; Bronson R; Jackson S; Donahue RE; High KA; Mingozzi F; Ng CY; Zhou J; Spence Y; McCarville MB; Valentine M; Allay J; Coleman J; Sleep S; Gray JT; Nienhuis AW; Davidoff AM
    Mol Ther; 2011 May; 19(5):876-85. PubMed ID: 21245849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
    Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
    Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine.
    McIntosh JH; Cochrane M; Cobbold S; Waldmann H; Nathwani SA; Davidoff AM; Nathwani AC
    Gene Ther; 2012 Jan; 19(1):78-85. PubMed ID: 21716299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stable human FIX expression after 0.9G intrauterine gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques.
    Mattar CN; Nathwani AC; Waddington SN; Dighe N; Kaeppel C; Nowrouzi A; Mcintosh J; Johana NB; Ogden B; Fisk NM; Davidoff AM; David A; Peebles D; Valentine MB; Appelt JU; von Kalle C; Schmidt M; Biswas A; Choolani M; Chan JK
    Mol Ther; 2011 Nov; 19(11):1950-60. PubMed ID: 21629224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.
    Nathwani AC; Gray JT; Ng CY; Zhou J; Spence Y; Waddington SN; Tuddenham EG; Kemball-Cook G; McIntosh J; Boon-Spijker M; Mertens K; Davidoff AM
    Blood; 2006 Apr; 107(7):2653-61. PubMed ID: 16322469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Utero Transfer of Adeno-Associated Viral Vectors Produces Long-Term Factor IX Levels in a Cynomolgus Macaque Model.
    Mattar CNZ; Gil-Farina I; Rosales C; Johana N; Tan YYW; McIntosh J; Kaeppel C; Waddington SN; Biswas A; Choolani M; Schmidt M; Nathwani AC; Chan JKY
    Mol Ther; 2017 Aug; 25(8):1843-1853. PubMed ID: 28462816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.
    Martino AT; Suzuki M; Markusic DM; Zolotukhin I; Ryals RC; Moghimi B; Ertl HC; Muruve DA; Lee B; Herzog RW
    Blood; 2011 Jun; 117(24):6459-68. PubMed ID: 21474674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction.
    Nakai H; Thomas CE; Storm TA; Fuess S; Powell S; Wright JF; Kay MA
    J Virol; 2002 Nov; 76(22):11343-9. PubMed ID: 12388694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses.
    Jayandharan GR; Zhong L; Sack BK; Rivers AE; Li M; Li B; Herzog RW; Srivastava A
    Hum Gene Ther; 2010 Mar; 21(3):271-83. PubMed ID: 19788390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype.
    Grimm D; Pandey K; Nakai H; Storm TA; Kay MA
    J Virol; 2006 Jan; 80(1):426-39. PubMed ID: 16352567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B.
    Brown HC; Doering CB; Herzog RW; Ling C; Markusic DM; Spencer HT; Srivastava A; Srivastava A
    Hum Gene Ther; 2020 Oct; 31(19-20):1114-1123. PubMed ID: 32657150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of liver gene transfer following peripheral intravascular delivery of adeno-associated virus (AAV)-5 and AAV-6 in a large animal model.
    Favaro P; Finn JD; Siner JI; Wright JF; High KA; Arruda VR
    Hum Gene Ther; 2011 Jul; 22(7):843-52. PubMed ID: 21126217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of gene transfer to the murine liver following intraperitoneal and intraportal delivery of hepatotropic AAV pseudo-serotypes.
    Dane AP; Wowro SJ; Cunningham SC; Alexander IE
    Gene Ther; 2013 Apr; 20(4):460-4. PubMed ID: 22895507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA.
    Nathwani AC; Davidoff A; Hanawa H; Zhou JF; Vanin EF; Nienhuis AW
    Blood; 2001 Mar; 97(5):1258-65. PubMed ID: 11222368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector.
    Mingozzi F; Schüttrumpf J; Arruda VR; Liu Y; Liu YL; High KA; Xiao W; Herzog RW
    J Virol; 2002 Oct; 76(20):10497-502. PubMed ID: 12239326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy.
    Grimm D; Zhou S; Nakai H; Thomas CE; Storm TA; Fuess S; Matsushita T; Allen J; Surosky R; Lochrie M; Meuse L; McClelland A; Colosi P; Kay MA
    Blood; 2003 Oct; 102(7):2412-9. PubMed ID: 12791653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.